TITLE

The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort

AUTHOR(S)

Altmann, Mathias; an der Heiden, Matthias; Scheufele, Ramona; Hartmann, Katrin; Houareau, Claudia; Bartmeyer, Barbara; Hamouda, Osamah

PUB. DATE

January 2012

SOURCE

BMC Infectious Diseases;2012, Vol. 12 Issue 1, p94

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: With ageing of the HIV-infected population, long-term exposure to treatment, varying adherence, emerging resistance and complications to therapies, effectiveness of Highly Active Antiretroviral Therapy (HAART) needs to be monitored continuously at the population level. The German HIV-1 Seroconverter Cohort is a multi-centre, open, long-term observational cohort including patients with a known or reliably estimated date of HIV-infection -i.e. last negative and first positive HIV antibody test within a maximum three-year interval or laboratory evidence of seroconversion. Our study aims to investigate survival improvements and changes in AIDS risk over calendar periods in the German HIV-1 Seroconverter Cohort. Methods: Retrospective (for the pre-1997 period) and prospective (since 1997) data from the German HIV-1 Seroconverter Cohort were used. Time from seroconversion to first AIDS-defining event over calendar periods was analysed by using Cox models adjusting for age at seroconversion, sex, transmission groups and short HIV test interval. Kaplan-Meier methods were used to determine expected survival (remaining AIDS-free) by calendar period. Results: 2162 seroconverters with 8976 person-years of observation were included in our analysis (up to 31.12.2010). A total of 196 first AIDS-defining events were reported. Two periods -i.e. 1997-2000 and 2007-2010- were statistically associated with a reduction in the risk of AIDS, accounting for an overall reduction of 80%. Compared to1997-2000, hazard ratios were 2.6 (95%CI, 1.6-4.8; p = 0.000) in pre-1997 and 0.5 (95%CI, 0.3-0.8; p = 0.007) in 2007-2010. Independent risk factor for AIDS progression was age at seroconversion (HR, 1.3 per 10 year-increase; p = 0.001). Conclusion: HAART effectiveness has improved in the German HIV-1-Seroconverter Cohort. The risk to develop AIDS decreased significantly in 1997-2000 and in 2007-2010. However, elderly may require particular monitoring in view of their faster progression to AIDS.

ACCESSION #

84227420

 

Related Articles

• Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

  Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

• Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

  Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

• Characterization of Antibodies to Human Immunodeficiency Viral Proteins in the Sera of HIV Infected and Non HIV Infected HBsAg Seropositive Patients. Olaniyan, Mathew Folaranmi // Global Journal of Health Science;Apr2010, Vol. 2 Issue 1, p193 

  This work was designed to characterize the HIV viral antibodies in HIV infected and non-HIV infected HBsAg seropositive patients. Fifty non HIV infected (male = 25; female = 25)and 50 HIV infected HBsAg seropositive patients (male - n = 25; female - n = 25) aged 6 - 64 years recruited from the...

• Engagement with HIV Prevention Treatment and Care among Female Sex Workers in Zimbabwe: a Respondent Driven Sampling Survey. Cowan, Frances M.; Mtetwa, Sibongile; Davey, Calum; Fearon, Elizabeth; Dirawo, Jeffrey; Wong-Gruenwald, Ramona; Ndikudze, Theresa; Chidiya, Samson; Benedikt, Clemens; Busza, Joanna; Hargreaves, James R. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

  Objective(S):To determine the HIV prevalence and extent of engagement with HIV prevention and care among a representative sample of Zimbabwean sex workers working in Victoria Falls, Hwange and Mutare. Design:Respondent driven sampling (RDS) surveys conducted at each site. Methods:Sex...

• Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

  Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

• Abnormal Cytokine Production by Circulating Monocytes and Dendritic Cells of Myeloid Origin in ART-Treated HIV-1+ Patients Relates to CD4+ T-Cell Recovery and HCV Co-Infection. Almeida, Maria; Cordero, Miguel; Almeida, Julia; Orfao, Alberto // Current HIV Research;Jul2007, Vol. 5 Issue 3, p325 

  HIV-1 infection is associated with dysregulation of cytokine production by peripheral blood (PB) monocytes and dendritic cells (DC), but controversial results have been reported. We aimed to analyze the effect of antiretroviral therapy (ART) on the in vitro production of inflammatory cytokines...

• Gynaecomastia associated with saquinavir therapy. Donovan, Basil; Bodsworth, Neil J.; Mulhall, Brian P.; Allen, Debbie; Donovan, B; Bodsworth, N J; Mulhall, B P; Allen, D // International Journal of STD & AIDS;Jan1999, Vol. 10 Issue 1, p49 

  Gynaecomastia has been reported in an HIV-1- infected man treated with a triple antiviral regimen including indinavir1. We describe 4 cases of men with gynaecomastia associated with saquinavir (hard gel capsule) therapy who denied taking any hormonal supplements or opiates.

• Physical Symptoms, Beliefs About Medications, Negative Mood, and Long-Term HIV Medication Adherence. Gonzalez, Jeffrey S.; Penedo, Frank J.; Llabre, Maria M.; Durán, Ron E.; Antoni, Michael H.; Schneiderman, Neil; Horne, Rob // Annals of Behavioral Medicine;2007, Vol. 34 Issue 1, p46 

  Background: Near-perfect levels of HIV medication adherence are necessary for treatment to be successful. However, many patients continue to report nonadherence to HIV treatment. Purpose: This study examines the relationship between symptoms of HIV and medication adherence and evaluates beliefs...

• Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2005, Vol. 19 Issue 10, p696 

  Reports several developments related to antiviral agents worldwide. Accounts on the reaction of HIV viral load to ritonavir-boosted atazanavir used as monotherapy; Analysis by Great Britain researchers on the benefit of highly active antiretroviral therapy when compared to no treatment in...

Read the Article